Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities

  |  

Biosimilar legislation
Finally, the ACR is examining and commenting on state-level biosimilar legislation, says Dr. Blumstein.

“In some states, biosimilars can be substituted at the pharmacy for another drug that it’s biosimilar to,” says Dr. Worthing. “The ACR is advocating for pharmacists to [be required to] inform patients and prescribers of these substitutions, and we’re also asking for that to happen prior to substitution or as soon as possible after.”

ADVERTISEMENT
SCROLL TO CONTINUE

According to the National Conference of State Legislatures, 36 states have drafted bills around biosimilars, but they vary in their notification or communication of substitution requirements.

National Advocacy as a Model
Overall, Dr. Blumstein would like to see ACR’s strong national advocacy reimagined for state-level efforts. “State legislation usually happens pretty fast,” he says. He believes the ACR’s Key Contact Program, which helps foster relationships between members and legislators, provides a solid foundation. It would require the identification of members willing and able to visit state capitols, sign on to editorials and more.

ADVERTISEMENT
SCROLL TO CONTINUE

“We have a model of what it would run like [and] how it would look, and I think that would mirror the federal efforts,” Dr. Blumstein says.

____________________________________________________________________

Kelly April Tyrrell writes about health, science and health policy. She lives in Madison, Wis.

Reference

  1. Corlette S, Williams A, Giovannelli J. State efforts to reduce consumers’ cost-sharing for prescription drugs. The Commonwealth Fund Blog. 2015 Nov 16. http://www.commonwealthfund.org/publications/blog/2015/nov/state-efforts-to-reduce-consumers-cost-sharing-for-prescription-drugs.

Related Articles

    N.Y. Rheumatologist Makes Advocacy a Priority

    In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…

    Howard Blumstein, MD, Assumes RheumPAC Chair

    “Advocacy is not about bribery. There’s nothing dirty about advocating for your patients and the future of your profession in terms of workforce, therapeutic advances and the financial viability of our practices. It’s our duty to do this,” he says. In his new role as the RheumPAC chair, he wants to help ACR/ARP members “see how vital these activities are to the success of our profession.”

    The ACR and Partners Help Get Legislation Passed in New York to Limit Step Therapy

    In June, state lawmakers in New York passed legislation on step therapy designed to help ensure patient access to the best and most appropriate care. Step therapy mandates that a patient with a specific condition receive prescribed drugs approved for that condition in the order that an insurance company determines it will cover as the…

    The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy

    A majority of state legislatures have concluded their work for 2016. The ACR’s state advocacy efforts continued to focus on policy benefiting rheumatologists and patients alike. The two dominant issues this year were biosimilar substitution and step therapy. Biosimilar Substitution Biosimilar substitution remains the most prevalent issue throughout the states. The ACR continues to monitor…